E-LIB Suche - Ergebnisse für: Bass, Ann D

1

Cladribine Tablets in Patients With Relapsing-Remitting Mul..:

Miravalle, Augusto A. ; Katz, Joshua ; Robertson, Derrick...
Neurology. 98 (2022) 18_supplement - p. , 2022

2

The sequential natalizumab – alemtuzumab therapy in patient..:

Hussain, Rehana Z ; Sguigna, Peter V ; Okai, Annette...
Journal of Central Nervous System Disease. 14 (2022) - p. 117957352211239 , 2022

Link: https://doi.org/10.1177/..

3

Alemtuzumab outcomes by age: Post hoc analysis from the ran..:

Bass, Ann D. ; Arroyo, Rafael ; Boster, Aaron L....
Multiple Sclerosis and Related Disorders. 49 (2021) - p. 102717 , 2021

Link: https://doi.org/10.1016/..

4

Safety evaluation of shorter infusion for ocrelizumab in a ..:

Bermel, Robert A. ; Waubant, Emmanuelle ; Pardo, Gabriel...
Annals of Clinical and Translational Neurology. 8 (2021) 3 - p. 711-715 , 2021

Link: https://doi.org/10.1002/..

5

B cell depletion changes the immune cell profile in multipl..:

Lovett-Racke, Amy E. ; Yang, Yuhong ; Liu, Yue...
Journal of Neuroimmunology. 359 (2021) - p. 577676 , 2021

Link: https://doi.org/10.1016/..

6

Autoimmunity and long-term safety and efficacy of alemtuzum..:

Coles, Alasdair J ; Jones, Joanne L ; Vermersch, Patrick...
Multiple Sclerosis Journal. 28 (2021) 5 - p. 842-846 , 2021

Link: https://doi.org/10.1177/..

7

Efficacy and safety of alemtuzumab over 6 years: final resu..:

Coles, Alasdair J. ; Arnold, Douglas L. ; Bass, Ann D....
Therapeutic Advances in Neurological Disorders. 14 (2021) - p. 175628642098213 , 2021

Link: https://doi.org/10.1177/..

8

CLICK-MS and MASTER-2 Phase IV Trial Design: Cladribine Tab..:

Miravalle, Augusto A ; Katz, Joshua ; Robertson, Derrick...
Neurodegenerative Disease Management. 11 (2021) 2 - p. 99-111 , 2021

Link: https://doi.org/10.2217/..

9

Efficacy and Safety of Alemtuzumab Through 9 Years of Follo..:

Ziemssen, Tjalf ; Bass, Ann D. ; Berkovich, Regina...
CNS Drugs. 34 (2020) 9 - p. 973-988 , 2020

Link: https://doi.org/10.1007/..

10

Real-world evaluation of effectiveness and safety of cladri..:

Fox, Edward ; Bass, Ann ; Hayward, Brooke...
Neurology. 94 (2020) 15_supplement - p. , 2020

Link: https://doi.org/10.1212/..

11

Alemtuzumab Maintains Efficacy on Clinical and MRI Disease ..:

Bass, Ann D. ; Alroughani, Raed ; Broadley, Simon...
Neurology. 94 (2020) 15_supplement - p. , 2020

Link: https://doi.org/10.1212/..

12

Long-term Follow-up Results from the Phase 2 Multicenter St..:

Fox, Edward ; Wray, Sibyl ; Shubin, Richard...
Neurology. 94 (2020) 15_supplement - p. , 2020

Link: https://doi.org/10.1212/..

13

Efficacy of a Fourth Alemtuzumab Course in RRMS Patients fr..:

Alroughani, Raed ; Traboulsee, Anthony ; Boster, Aaron...
Multiple Sclerosis and Related Disorders. 37 (2020) - p. 101585 , 2020

Link: https://doi.org/10.1016/..

14

Long-term efficacy and safety of alemtuzumab in patients wi..:

Steingo, Brian ; Al Malik, Yaser ; Bass, Ann D....
Journal of Neurology. 267 (2020) 11 - p. 3343-3353 , 2020

Link: https://doi.org/10.1007/..

15

Immune thrombocytopenia in alemtuzumab-treated MS patients:..:

Cuker, Adam ; Bass, Ann D ; Nadj, Congor...
Multiple Sclerosis Journal. 26 (2019) 1 - p. 48-56 , 2019

Link: https://doi.org/10.1177/..